Skip to main content

Overview

The major aim of this proposed research is to examine whether patient quality of life and length of survival is impacted by the Comprehensive Health Enhancement Support System-Lung Cancer (CHESS-LC) intervention. To accomplish this, we will conduct a longitudinal, randomized clinical trial comparing the CHESS-LC intervention to an Internet Control group. The primary aims and related hypotheses are:

  1. Determine the impact of CHESS-LC on patient quality of life. We hypothesize that at 6 and 12 months post-test, quality of life will be greater among CHESS-LC users compared to the control group.
  2. Determine the impact of CHESS-LC on patient survival. Compared to a Usual Care Control, CHESS-LC patients will have greater median survival.

The Need

The prognosis for Non-Small Cell Lung Cancer patients remains poor despite recent advances in anti-cancer therapies, with a median lifespan of eight months. Our current CECCR Lung Cancer Clinician Integration (LCCI) project was designed to measure the impact of CHESS (Comprehensive Health Enhancement Support System), on lung cancer caregivers' quality of life (QOL) and bereavement. However, preliminary data analysis has yielded an unanticipated finding that such an ICCS may even have a survival benefit. Specifically, one year survival was significantly increased in the CHESS group (50%) compared to the Internet (34.2%). In addition to examining the quality of life outcomes from patient use of an ICCS during advanced cancer treatment, the proposed research will be the first assessment to our knowledge of whether providing patients and caregivers with an ICCS can affect length of survival in an advanced lung cancer setting. This study will test two primary hypotheses:

  1. Determine the impact of CHESS-LC on patient quality of life. We hypothesize that at 6 and 12 months post test, quality of life will be greater among CHESS-LC users compared to the control group.
  2. Determine the impact of CHESS-LC on patient survival. Compared to a Usual Care Control, CHESS-LC patients will have greater median survival.

Details

Recruitment for this study began in December 2009 and will continue through April 2012. Study participants are recruited from national cancer centers in WI, TX, IL, and CT. Participants will be offered a laptop with internet access for 12 months. Patients and their Caregivers will be asked to complete eight surveys at pretest, 2, 4, 6, 8, 10, 12, and 18 months. All participants are reimbursed for completing surveys and their internet costs while on study. Individual system training and technical support is provided by CHESS staff through the duration of the study.

Principal Investigators:
Lori DuBenske, Ph.D